Germany's Fresenius said it was checking options to speed up the start of new production lines of medical equipment at a ...

Fresenius Kabi and Formycon have won US Food and Drug Administration (FDA) approval for Otulfi (ustekinumab-aauz), a ...

Shares of Claris Lifesciences climbed 8 percent intraday on Monday on settlement of litigations & licence agreement for anesthetic with US company. Advisory Alert: It has come to our attention ...

Aurora™ is the automated system that streamlines plasma collection, producing virtually cell-free plasma and providing an improved experience for both operators and donors. The system separates ...

Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, and ...

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz) Otulfi TM received FDA approval for both subcutaneous and intravenous formulations, to treat the same ...

Otulfi is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active ...

Hospitals are deploying strategies to conserve medical IV solutions after Baxter's North Carolina facility was damaged by ...

Fresenius Kabi, in partnership with Formycon AG, has received European Commission approval for Otulfi®, a biosimilar of ...

PLANEGG-MARTINSRIED, Germany I7, 2024 I Formycon AG (FSE: FYB, “Formycon”) and its commercialization partner Fresenius Kabi jointly announce that ...

Germany's Fresenius said it is checking options to start new infusion-solution production lines faster than planned at a ...